ITNS Stock Overview
A development stage company, focuses on producing and marketing over the counter and prescription homeopathic preparations to treat common ailments and chronic diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Itonis, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0004 |
| 52 Week High | US$0.0013 |
| 52 Week Low | US$0.00019 |
| Beta | 0 |
| 11 Month Change | -20.00% |
| 3 Month Change | 0% |
| 1 Year Change | -11.11% |
| 33 Year Change | -75.00% |
| 5 Year Change | -55.56% |
| Change since IPO | -99.76% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| ITNS | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -20.0% | 2.6% | 0.5% |
| 1Y | -11.1% | 13.1% | 30.7% |
Return vs Industry: ITNS underperformed the US Pharmaceuticals industry which returned 14.2% over the past year.
Return vs Market: ITNS underperformed the US Market which returned 32.3% over the past year.
Price Volatility
| ITNS volatility | |
|---|---|
| ITNS Average Weekly Movement | 39.8% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ITNS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ITNS's weekly volatility has decreased from 50% to 40% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | n/a | Mark Cheung | www.itonisholdings.com |
Itonis, Inc., a development stage company, focuses on producing and marketing over the counter and prescription homeopathic preparations to treat common ailments and chronic diseases. The company intends to sells its over-the-counter to alleviate mild to moderate nausea. It has placed a manufacturing order for the first batch of its Emesyl product line.
Itonis, Inc. Fundamentals Summary
| ITNS fundamental statistics | |
|---|---|
| Market cap | US$609.36k |
| Earnings (TTM) | -US$1.39m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs ITNS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ITNS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$1.39m |
| Earnings | -US$1.39m |
Last Reported Earnings
Nov 30, 2011
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did ITNS perform over the long term?
See historical performance and comparison